Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy

Klinik für Anästhesiologie

Status: Withdrawn

Conditions: Kidney Replacement Disorder

Study type: Observational

Funder types: Other

Identifiers

NCT01276392

01-AHTSDKM

Details and patient eligibility

About

Actual clinical practice predominantly makes use of heparin (systemically) or citrate regionally as anticoagulation in the extracorporeal circulation for renal replacement therapy. We aim to find out if different anticoagulation strategies may lead to different levels of platelet activation and whole blood coagulation. Regarding coagulation activation, it remains uncertain if there is an advantage for one of these methods. However, it is of major interest to minimize the risk of any additional clotting activation via extracorporeal circulation in these usually critically ill patients.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years, acute renal failure with need for continuous veno-venous renal replacement therapy

Exclusion criteria

• Age < 18 years, pregnancy, contraindications for one of the two anticoagulation methods, missing informed consent or disagreement in the progress of the study

Trial design

0 participants in 2 patient groups

Heparin

Description:

10 Patients undergoing continuous renal replacement therapy using heparin for providing anticoagulation. Blood samples taken at 8 predefined timepoints.

CiCa

Description:

10 Patients undergoing continuous renal replacement therapy using citrate for providing anticoagulation. Blood samples taken at 8 predefined timepoints.